News and Trends 19 Oct 2017 Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […] October 19, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’ Gilead’s CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis’ CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T therapy to be approved in the US. The FDA has authorized its use to treat aggressive B-cell non-Hodgkin lymphoma in patients for whom at least two […] October 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and invest €45M in equity to kick off a collaboration for the development and commercialization of up to five mRNA vaccines for cancer. CureVac could receive up […] October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 German Researchers Set the Immune System Free to Fight Against Cancer There could be a way to stop cancers escaping from the immune system, and researchers hope to use this for more effective cancer treatments. Researchers at Universität Bonn have found a way to “release the brakes” in the immune system that helps cancers to survive. Cancers benefit from this by pretending to be regular cells, […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data OncoDNA is gathering prestigious oncology centers to take part in Moncodaneum, an international project to bring precision medicine to cancer patients. The Belgian biotech OncoDNA has announced that it will be collaborating with the Strasbourg University Hospital, France, and the Oncology Center of Bydgoszcz, Poland, in the advancement of precision medicine for cancer. The two […] October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 18 Oct 2017 Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer? Everything you need to know about CAR-T, a revolutionary cell therapy for cancer. You might have heard of CAR-T cell therapy as a “miracle cure” for cancer. The approval of Novartis’ Kymriah, the first CAR-T therapy, made headlines in August as it was the first gene-edited cell therapy for cancer to make it to the […] October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 9 Oct 2017 The Woman Developing the Next Generation of Cancer Immunotherapy Özlem Türeci discusses the future of individualized cancer therapy and her journey to become an entrepreneur and take science to patients. As a trained physician and immunologist, Dr. Özlem Türeci has led her own research group with Prof. Ugur Sahin at the University of Mainz, Germany, since 2000. But academic research was not enough for her, […] October 9, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2017 Study Reveals No Evidence to Support Most European Cancer Drug Approvals A new study concludes the majority of cancer drugs approved by the EMA between 2009 and 2013 weren’t backed by sufficient evidence that they are effective. A team of researchers from King’s College London and the London School of Economics has published a new study reviewing the clinical data used to back the approval of […] October 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 British Biotech To Raise £12.2M to Finish Off Liquid Biopsy Technology Angle will raise £12.2M, which will allow it to acquire assets from Axela to put the finishing touches to its full liquid biopsies solution. Angle is a leader in the liquid biopsy market, the ‘holy grail’ of cancer diagnostics. The company has developed technology that recently outperformed the gold standard in the field. Angle is hoping to raise £12.2M […] October 5, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […] October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 4 Oct 2017 4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […] October 4, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 German Pharma Enters the Clinic with Solid Tumor Treatment A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its […] September 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email